CTOs on the Move

Breckenridge Pharmaceutical

www.bpirx.com

 
Breckenridge Pharmaceutical Inc. is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.bpirx.com
  • 1141 S Rogers Cir Ste 3
    Boca Raton, FL USA 33487
  • Phone: 561.443.3314

Executives

Name Title Contact Details

Similar Companies

Legacy Pharmaceuticals International

Legacy Pharmaceuticals International is a Humacao, PR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Dunn Group

The Dunn Group is a Totowa, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bactolac Pharmaceutical Inc

We are completely committed to the success of every one of our client-partners and dedicate ourselves to quality and efficiency. We provide custom formulation and quality manufacturing for your existing formulas and welcome the opportunity to provide

ABIANT INC

ABIANT INC is a Deerfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.